{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:53:43Z","timestamp":1793332423202,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Convoy Therapeutics Inc","award":["SB120129"],"award-info":[{"award-number":["SB120129"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.jconrel.2014.11.015","type":"journal-article","created":{"date-parts":[[2014,12,4]],"date-time":"2014-12-04T02:56:53Z","timestamp":1417661813000},"page":"190-197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["Topical delivery of Cyclosporine A into the skin using SPACE-peptide"],"prefix":"10.1016","volume":"199","author":[{"given":"Ming","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunny","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron C.","family":"Anselmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah H.","family":"Slee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Muraski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Mitragotri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2014.11.015_bb0005","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/BF01973261","article-title":"Biological effects of cyclosporin-a \u2014 new antilymphocytic agent","volume":"6","author":"Borel","year":"1976","journal-title":"Agents Actions"},{"key":"10.1016\/j.jconrel.2014.11.015_bb0010","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJM197909063011015","article-title":"Cyclosporin a for psoriasis","volume":"301","author":"Mueller","year":"1979","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2014.11.015_bb0015","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1001\/jama.1986.03380220076026","article-title":"Cyclosporine improves psoriasis in a double-blind-study","volume":"256","author":"Ellis","year":"1986","journal-title":"JAMA"},{"key":"10.1016\/j.jconrel.2014.11.015_bb0020","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1136\/bmj.293.6554.1098-c","article-title":"Clearance of psoriasis with low-dose cyclosporine","volume":"293","author":"Brookes","year":"1986","journal-title":"Br. Med. J."},{"key":"10.1016\/j.jconrel.2014.11.015_bb0025","first-page":"453","article-title":"Clearance of psoriasis with low-dose cyclosporine-A","volume":"116","author":"Griffiths","year":"1987","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jconrel.2014.11.015_bb0030","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/0190-9622(92)70012-5","article-title":"Cyclosporine in psoriasis \u2014 a multicenter dose-finding study in severe plaque psoriasis","volume":"26","author":"Christophers","year":"1992","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jconrel.2014.11.015_bb0035","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.0366-077X.2004.05949.x","article-title":"Ciclosporin in psoriasis clinical practice: an international consensus statement","volume":"150","author":"Griffiths","year":"2004","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jconrel.2014.11.015_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2133.2006.07343.x","article-title":"Update on the use of ciclosporin in immune-mediated dermatoses","volume":"155","author":"Griffiths","year":"2006","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jconrel.2014.11.015_bb0045","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1610-0387.2008.06834.x","article-title":"Systemic therapeutic options for severe atopic dermatitis","volume":"7","author":"Bussmann","year":"2009","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"10.1016\/j.jconrel.2014.11.015_bb0050","doi-asserted-by":"crossref","first-page":"9","DOI":"10.5021\/ad.2010.22.1.9","article-title":"The efficacy and safety of long-term oral cyclosporine treatment for patients with atopic dermatitis","volume":"22","author":"Haw","year":"2010","journal-title":"Ann. Dermatol."},{"key":"10.1016\/j.jconrel.2014.11.015_bb0055","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/0190-9622(90)70032-D","article-title":"Oral cyclosporine for the treatment of alopecia-areata \u2014 a clinical and immunohistochemical analysis","volume":"22","author":"Gupta","year":"1990","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jconrel.2014.11.015_bb0060","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/j.1365-2133.2012.10955.x","article-title":"British association of dermatologists' guidelines for the management of alopecia areata 2012","volume":"166","author":"Messenger","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jconrel.2014.11.015_bb0065","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1046\/j.1468-3083.2002.00570_5.x","article-title":"Cyclosporin A and alopecia areata","volume":"16","author":"Moreno","year":"2002","journal-title":"J. Eur. Acad. Dermatol."},{"key":"10.1016\/j.jconrel.2014.11.015_bb0070","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.jaad.2010.02.063","article-title":"The use of cyclosporine in dermatology: part I","volume":"63","author":"Amor","year":"2010","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jconrel.2014.11.015_bb0075","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jaad.2010.02.062","article-title":"The use of cyclosporine in dermatology: part II","volume":"63","author":"Ryan","year":"2010","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jconrel.2014.11.015_bb0080","first-page":"979","article-title":"The use of cyclosporine in dermatology","volume":"11","author":"Dehesa","year":"2012","journal-title":"J. Drugs Dermatol."},{"key":"10.1016\/j.jconrel.2014.11.015_bb0085","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2165\/00003088-200039020-00003","article-title":"Impact of absorption profiling on efficacy and safety of cyclosporin therapy in transplant recipients","volume":"39","author":"Belitsky","year":"2000","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2014.11.015_bb0090","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/jps.2600840512","article-title":"Percutaneous absorption and dermal delivery of cyclosporin A","volume":"84","author":"Choi","year":"1995","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2014.11.015_bb0095","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S0140-6736(87)92829-7","article-title":"Topical cyclosporine and psoriasis","volume":"1","author":"Griffiths","year":"1987","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jconrel.2014.11.015_bb0100","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004413.pub2","article-title":"Interventions for alopecia areata","volume":"16","author":"Delamere","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jconrel.2014.11.015_bb0105","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/0190-9622(90)70015-A","article-title":"Intralesional cyclosporine in the treatment of psoriasis \u2014 a clinical, immunological, and pharmacokinetic study","volume":"22","author":"Ho","year":"1990","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jconrel.2014.11.015_bb0110","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1365-2133.1991.tb14783.x","article-title":"Clearing of pyoderma gangrenosum by intralesional cyclosporin A","volume":"125","author":"Mrowietz","year":"1991","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jconrel.2014.11.015_bb0115","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ijpharm.2006.07.022","article-title":"Investigation into the potential of low-frequency ultrasound facilitated topical delivery of cyclosporin A","volume":"326","author":"Liu","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2014.11.015_bb0120","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ijpharm.2004.01.016","article-title":"Iontophoresis of lecithin vesicles of cyclosporin A","volume":"274","author":"Boinpally","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2014.11.015_bb0125","first-page":"191","article-title":"Investigation into the potential of electroporation facilitated topical delivery of cyclosporin a","volume":"64","author":"Liu","year":"2010","journal-title":"J. Pharm. Sci. Technol."},{"key":"10.1016\/j.jconrel.2014.11.015_bb0130","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejpb.2004.12.003","article-title":"Topical delivery of cyclosporin A: an in vitro study using monoolein as a penetration enhancer","volume":"60","author":"Lopes","year":"2005","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2014.11.015_bb0135","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/81359","article-title":"Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation","volume":"6","author":"Rothbard","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2014.11.015_bb0140","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ijpharm.2005.12.029","article-title":"Effect of vehicles and enhancers on the topical delivery of cyclosporin A","volume":"311","author":"Liu","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2014.11.015_bb0145","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1023\/B:PHAM.0000045239.22049.70","article-title":"Amphiphilogels for drug delivery: formulation and characterization","volume":"21","author":"Jibry","year":"2004","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2014.11.015_bb0150","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0378-5173(99)00361-0","article-title":"Lecithin vesicular carriers for transdermal delivery of cyclosporin A","volume":"194","author":"Guo","year":"2000","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2014.11.015_bb0155","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jconrel.2004.02.028","article-title":"Synergistic penetration enhancement effect of ethanol and phospholipids on the topical delivery of cyclosporin A","volume":"97","author":"Verma","year":"2004","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2014.11.015_bb0160","doi-asserted-by":"crossref","first-page":"15816","DOI":"10.1073\/pnas.1016152108","article-title":"Delivery of siRNA and other macromolecules into skin and cells using a peptide enhancer","volume":"108","author":"Hsu","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2014.11.015_bb0165","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jconrel.2013.10.007","article-title":"Topical delivery of hyaluronic acid into skin using SPACE-peptide carriers","volume":"173","author":"Chen","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2014.11.015_bb0170","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jconrel.2014.01.006","article-title":"Topical delivery of siRNA into skin using SPACE-peptide carriers","volume":"179","author":"Chen","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2014.11.015_bb0175","doi-asserted-by":"crossref","DOI":"10.1093\/clinchem\/16.1.24","article-title":"Quantification of protein solutions with trinitrobenzenesulfonic acid","volume":"16","author":"Goodwin","year":"1970","journal-title":"Clin. Chem."},{"key":"10.1016\/j.jconrel.2014.11.015_bb0180","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2174\/156720106777731091","article-title":"Current developments using emerging transdermal technologies in physical enhancement methods","volume":"3","author":"Nanda","year":"2006","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.jconrel.2014.11.015_bb0185","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jconrel.2005.10.012","article-title":"Relationships between skin's electrical impedance and permeability in the presence of chemical enhancers","volume":"110","author":"Karande","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2014.11.015_bb0190","first-page":"965","article-title":"Enhanced oral bioavailability of cyclosporine A by liposomes containing a bile salt","volume":"6","author":"Guan","year":"2011","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2014.11.015_bb0195","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/0192-0561(92)90155-E","article-title":"Effects of subcutaneous versus intravenous administration of cyclosporin A on rat thymic histology and pharmacokinetics","volume":"14","author":"de Waal","year":"1992","journal-title":"Int. J. Immunopharmacol."},{"key":"10.1016\/j.jconrel.2014.11.015_bb0200","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1002\/jps.20898","article-title":"Gelatin-stabilised microemulsion-based organogels facilitates percutaneous penetration of cyclosporin A in vitro and dermal pharmacokinetics in vivo","volume":"96","author":"Liu","year":"2007","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2014.11.015_bb0205","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.2042-7158.1991.tb06688.x","article-title":"Unusual solubility behavior of cyclosporine-a in aqueous-media","volume":"43","author":"Ismailos","year":"1991","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.jconrel.2014.11.015_bb0210","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0378-5173(01)00634-2","article-title":"Transdermal delivery of naloxone: effect of water, propylene glycol, ethanol and their binary combinations on permeation through rat skin","volume":"219","author":"Panchagnula","year":"2001","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2014.11.015_bb0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0939-6411(97)00149-5","article-title":"Percutaneous penetration enhancement and its quantification","volume":"46","author":"Bach","year":"1998","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2014.11.015_bb0220","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ijpharm.2005.12.029","article-title":"Effect of vehicles and enhancers on the topical delivery of cyclosporin A","volume":"311","author":"Liu","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2014.11.015_bb0225","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1023\/B:PHAM.0000016235.32639.23","article-title":"Solubilizing excipients in oral and injectable formulations","volume":"21","author":"Strickley","year":"2004","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2014.11.015_bb0230","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1002\/jps.20898","article-title":"Gelatin-stabilised microemulsion-based organogels facilitates percutaneous penetration of cyclosporin a in vitro and dermal pharmacokinetics in vivo","volume":"96","author":"Liu","year":"2007","journal-title":"J. Pharm. Sci."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365914007639?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365914007639?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T10:47:23Z","timestamp":1598525243000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365914007639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":46,"alternative-id":["S0168365914007639"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2014.11.015","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Topical delivery of Cyclosporine A into the skin using SPACE-peptide","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2014.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}